Pharmacogenetic screening of the gene deletion and duplications of CYP2D6

Drug Metabolism Reviews

Volumn 39, Issue 1, 2007, Pages 45-60

  Meijerman, Irma ^a   Sanderson, Linda M ^b   Smits, Paul H M ^b   Beijnen, Jos H ^b   Schellens, Jan H M ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

Cytochrome 2D6; Gene deletion; Gene duplication; Pharmacogenetics

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; APRINDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; DESIPRAMINE; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; METOPROLOL; MEXILETINE; NEUROLEPTIC AGENT; OLANZAPINE; PERHEXILINE; PERPHENAZINE; PROPAFENONE; PROPRANOLOL; RISPERIDONE; THIORIDAZINE; TIMOLOL; UNINDEXED DRUG; ZUCLOPENTHIXOL;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; GENE DELETION; GENE DUPLICATION; GENE IDENTIFICATION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHERN BLOTTING;

ANIMALS; CYTOCHROME P-450 CYP2D6; GENE DELETION; GENE DUPLICATION; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 33847018803     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530600952206     Document Type: Article

References (55)

1. Abraham, A. (2001). Genetic polymorphism of CYP2D6. Indian J. Pharmacol. 33:147-169.
2. Armour, J. A., Barton, D. E., Cockburn, D. J., Taylor, G. R. (2002). The detection of large deletions or duplications in genomic DNA. Hum. Mutat. 20:325-337.
3. Barnes, W. M. (1994). PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. Proc. Natl. Acad. Sci. USA 91:2216-2220.
4. Bertilsson, L., Dahl, M. L., Dalen, P., Al-Shurbaji, A. (2002). Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53:111-122.
5. Bodin, L., Beaune, P. H., Loriot, M. A. (2005). Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J. Biomed. Biotechnol. 2005:248-253.
6. Bradford, L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243.
7. Broly, F., Marez, D., Sabbagh, N., Legrand, M., Millecamps, S., Lo Guidice, J. M., Boone, P., Meyer, U. A. (1995). An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384.
8. Cheng, S., Fockler, C., Barnes, W. M., Higuchi, R. (1994). Effective amplification of long targets from cloned inserts and human genomic DNA. Proc. Natl. Acad. Sci. USA 91:5695-5699.
9. Daly, A. K., Steen, V. M., Fairbrother, K. S., Idle, J. R. (1996). CYP2D6 multiallelism. Methods Enzymol. 272:199-210.
10. Endrizzi, K., Fischer, J., Klein, K., Schwab, M., Nussler, A., Neuhaus, P., Eichelbaum, M., Zanger, U. M. (2002). Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal. Biochem. 300:121-131.
11. Eriksson, S., Berg, L. M., Wadelius, M., Alderborn, A. (2002). Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev. Technol. 1:49-59.
12. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M., Meyer, U. A. (1991). Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 48:943-950.
13. Ginzinger, D. G. (2002). Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp. Hematol. 30:503-512.
14. Giovannetti, E., Mey, V., Danesi, R., Basolo, F., Barachini, S., Deri, M., Del Tacca, M. (2005). Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: Effects on cell survival, cell cycle and pharmacogenetic profile. Br. J. Cancer 92:681-689.
15. Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R., Mathieu, C. (2001). An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods 25:386-401.
16. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., Meyer, U. A. (1988a). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446.
17. Gonzalez, F. J., Vilbois, F., Hardwick, J. P., McBride, O. W., Nebert, D. W., Gelboin, H. V., Meyer, U. A. (1988b). Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2:174-179.
18. Gough, A. C., Smith, C. A., Howell, S. M., Wolf, C. R., Bryant, S. P., Spurr, N. K. (1993). Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 15:430-432.
19. Hanna, I. H., Dawling, S., Roodi, N., Guengerich, F. P., Parl, F. F. (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60:3440-3444.
20. Heim, M., Meyer, U. A. (1990). Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532.
21. Heim, M. H., Meyer, U. A. (1992). Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14:49-58.
22. Hengen, P. N. (1994). Methods and reagents. Long and accurate PCR. TIBS 19:341-342.
23. Hersberger, M., Marti-Jaun, J., Rentsch, K., Hanseler, E. (2000). Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin. Chem. 46:1072-1077.
24. Hiratsuka, M., Agatsuma, Y., Omori, F., Narahara, K., Inoue, T., Kishikawa, Y., Mizugaki, M. (2000). High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol. Pharm. Bull. 23:1131-1135.
25. Holland, P. M., Abramson, R .D., Watson, R., Gelfand, D. H. (1991). Detection of specific polymerase chain reaction product by utilizing the 5′ - 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl. Acad. Sci. USA 88:7276-7280.
26. Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 25:193-200.
27. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5:6-13.
28. Ingelman-Sundberg, M., Rodriguez-Antona, C. (2005). Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360:1563-1570.
29. Johansson, I., Lundqvist, E., Dahl, M. L., Ingelman-Sundberg, M. (1996). PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355.
30. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A., Gonzalez, F. J. (1989). The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45:889-904.
31. Kirchheiner, J., Fuhr, U., Brockmoller, J. (2005). Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat. Rev. Drug Discov. 4:639-647.
32. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M. L., Licinio, J., Roots, I., Brockmoller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9:442-473.
33. Ledesma, M. C., Agundez, J. A. (2005). Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin. Chem. 51:939-943.
34. Lovlie, R., Daly, A. K., Molven, A., Idle, J. R., Steen, V. M. (1996). Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392:30-34.
35. Lundqvist, E., Johansson, I., Ingelman-Sundberg, M. (1999). Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327-338.
36. Mattison, L. K., Soong, R., Diasio, R. B. (2002). Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485-492.
37. McLeod, H. L., Siva, C. (2002). The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98.
38. Meyer, U. A., Skoda, R. C., Zanger, U. M. (1990). The genetic polymorphism of debrisoquine/ sparteine metabolism-molecular mechanisms. Pharmacol. Ther. 46:297-308.
39. Mocellin, S., Rossi, C. R., Pilati, P., Nitti, D., Marincola, F. M. (2003). Quantitative real-time PCR: A powerful ally in cancer research. Trends Mol. Med. 9:189-195.
40. Muller, B., Zopf, K., Bachofer, J., Steimer, W. (2003). Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin. Chem. 49:1624-1631.
41. Murphy, G. M., Pollock, B. G., Kirshner, M. A., Pascoe, N., Cheuk, W., Mulsant, B. H., Reynolds, C. F. (2001). CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25:737-743.
42. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., Sadee, W. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286:2270-2279.
43. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., Breckenridge, A. M. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19.
44. Roberts, R., Joyce, P., Kennedy, M. A. (2000). Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum. Mutat. 16:77-85.
45. Roberts, R. L., Kennedy, M. A. (2006). Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin. Chim. Acta 366:348-351.
46. Schaeffeler, E., Schwab, M., Eichelbaum, M., Zanger, U. M. (2003). CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum. Mutat. 22:476-485.
47. Schur, B. C., Bjerke, J., Nuwayhid, N., Wong, S. H. (2001). Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin. Chim. Acta 308:25-31.
48. Sellner, L. N., Taylor, G. R. (2004). MLPA and MAPH: New techniques for detection of gene deletions. Hum. Mutat. 23:413-419.
49. Stedman, C., Robertson, G., Coulter, S., Liddle, C. (2004). Feed-forward regulation of bile acid detoxification by CYP3A4 - Studies in humanized transgenic mice. J. Biol. Chem. 279:11336-11343.
50. Steen, V. M., Andreassen, O. A., Daly, A. K., Tefre, T., Borresen, A. L., Idle, J. R., Gulbrandsen, A. K. (1995). Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223.
51. Steijns, L. S., Van Der Weide, J. (1998). Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin. Chem. 44:914-917.
52. Stuven, T., Griese, E. U., Kroemer, H. K., Eichelbaum, M., Zanger, U. M. (1996). Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6:417-421.
53. Topic, E., Stefanovic, M., Ivanisevic, A. M., Blazinic, F., Culav, J., Skocilic, Z. (2000). CYP2D6 genotyping in patients on psychoactive drug therapy. Clin. Chem. Lab. Med. 38:921-927.
54. Wilhelm, J., Pingoud, A. (2003). Real-time polymerase chain reaction. ChemBioChem. 4:1120-1128.
55. Zanger, U. M., Raimundo, S., Eichelbaum, M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369:23-37.